Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
With population aging, chronic kidney disease (CKD) is increasingly common among cancer patients. Real-world evidence on the effectiveness of adjuvant chemotherapy (AC) and the appropriateness of standard regimens in CKD remains limited. We previously showed that AC use in CKD was associated with better survival. This study evaluated (1) whether the association between AC and survival is modified by CKD, and (2) among AC recipients, whether the benefit of standard regimens differs by CKD status.
We linked a hospital-based cancer registry, Diagnosis Procedure Combination claims, and 5-year vital status for adults (≥20 years) with curatively resected gastric, colorectal, non–small-cell lung, or breast cancer diagnosed in 2012–2015. CKD was identified by diagnosis codes or characteristic prescriptions. Using a target-trial emulation with a 90-day postoperative landmark (sensitivity: 45 days), we compared initiation of AC vs no AC within 90 days. Background imbalance was addressed with stabilized inverse-probability weighting (age, sex, cancer type, CKD, ADL, comorbidity, and hospital type), and weighted Cox models estimated the AC×CKD interaction. In a secondary analysis restricted to patients who started AC within 90 days, multivariable Cox models from AC start assessed the interaction between standard regimens (standard) and CKD (adjusted for age, sex, cancer type, ADL, comorbidity, and hospital type).
Of 47,970 patients, 1,803 (3.8%) had CKD and 31,630 (65.9%) received AC. Among non-CKD patients, AC was associated with lower mortality (Hazard Ratio (HR) = 0.64; 95% Confidence Interval (CI) 0.62–0.67; p<0.001). In the absence of AC, CKD was associated with higher mortality (HR = 2.05; 95% CI 1.86–2.26; p<0.001). The interaction term for AC×CKD was null (HR = 0.99; 95% CI 0.84–1.18; p = 0.98), indicating no evidence that the relative AC benefit differed by CKD. Findings were consistent using a 45-day landmark.
Among AC recipients, use of a standard regimen was associated with better survival (HR = 0.93; 95% CI 0.88–0.99; p = 0.01), and CKD remained a risk factor (HR = 2.01; 95% CI 1.62–2.48; p<0.001). The standard90×CKD interaction was not significant (HR = 0.82; 95% CI 0.65–1.04; p = 0.11).
The relative survival benefit of AC appears preserved in patients with CKD, and, among AC recipients, standard regimens are associated with improved outcomes without evidence of diminished benefit in CKD. These findings argue against routine avoidance of AC solely due to CKD and support delivering standard adjuvant regimens whenever clinically feasible.
